As attached
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gujarat Inject Kerala Limited reported weak Q3 FY26 results with standalone net sales of ₹162.51 lakh, sharply down from ₹502.26 lakh in Q3 FY25. For the nine months ended December 2025, net sales fell to roughly ₹1,490 lakh versus about ₹1,977 lakh in the same period last year, a decline of around 25%. Profit after tax for Q3 stood at ₹3.80 lakh (vs ₹21.16 lakh in Q3 FY25), while 9M PAT came in at ₹94.40 lakh compared to ₹101.72 lakh last year. Basic EPS for 9M FY26 was ₹0.65 vs ₹0.70 in the prior year. The statutory auditor M/s. S. Mandawat & Co. issued an unmodified limited review report with no qualifications or emphasis of matter.
Sharply lower quarterly revenue and earnings signal continued business weakness, which is negative for shareholders and likely to weigh on the stock price given the deteriorating top-line trend despite PAT remaining positive on a nine-month basis.